Protection of Macaques against a SHIV with a Homologous HIV-1 Env and a Pathogenic SHIV-89.6P with a Heterologous Env by Vaccination with Multiple Gene-Deleted SHIVs

Ui, Masahiro; Kuwata, Takeo; Igarashi, Tatsuhiko; Ibuki, Kazuyasu; Miyazaki, Yasuaki; Kozyrev, Iouly L.; Enose, Yoshimi; Shimada, Toshihide; Uesaka, Hiromi; Yamamoto, Hiroshi; Miura, Tomoyuki; Hayami, Masanori

doi:10.1006/viro.1999.0049

Cited by 40 publications

(19 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…cDNA duplicates were amplified by SYBR green real-time PCR assay previously described (26) with some modifications. Briefly, primers that recognize specific and highly conserved sequences on the gag region of SIV described by Ui et al (27) were selected. The sequences of SIV gag primers were 5Ј-GGAAATTAC CCAGTACAACAAATAGG-3Ј and 5Ј-TCTATCAATTTTACCCAG GCATTTA-3Ј.…”

Section: Determination Of Shiv Rna Viral Load By Sybr Green-based Quamentioning

confidence: 99%

Effects of Immunization with CCR5-Based Cycloimmunogen on Simian/HIVSF162P3 Challenge

Misumi

Nakayama

Kusaba

et al. 2006

The Journal of Immunology

View full text Add to dashboard Cite

A synthetic cycloimmunogen targeting the HIV-1 coreceptor CCR5 was evaluated for its capacity to induce CCR5-specific Abs with anti-HIV-1 activity in cynomolgus macaques. The cyclic closed-chain dodecapeptide (cDDR5) mimicking the conformation-specific domain of human CCR5 was chemically prepared, in which the Gly-Glu dipeptide links the amino and carboxy termini of the decapeptidyl linear chain (Arg168 to Thr177) derived from the undecapeptidyl arch (Arg168 to Cys178) of extracellular loop-2 in CCR5. The immunization of cynomolgus macaques with the cDDR5-conjugated multiple-Ag peptide (cDDR5-MAP) induced anti-cDDR5 serum production for ∼15 wk after the third immunization. The antisera raised against cDDR5-MAP reacted with both human and macaque CCR5s, and potently suppressed infection by the R5 HIV-1 laboratory isolate (HIVJRFL), R5 HIV-1 primary isolates (clade A:HIV93RW004 and clade C:HIVMJ4), and a pathogenic simian/HIV (SHIVSF162P3) bulk isolate in vitro. To examine the prophylactic efficacy of anti-CCR5 serum Ab for acute HIV-1 infection, cynomolgus macaques were challenged with SHIVSF162P3. The cDDR5-MAP immunization attenuated the acute phase of SHIVSF162P3 replication. The geometric mean plasma viral load in the vaccinated macaques was 217.10 times lower than that of the control macaques at 1 wk postchallenge. Taken together, these results suggest that cDDR5-MAP immunization is an effective prophylactic vaccine strategy that suppresses and delays viral propagation during the initial HIV-1 transmission for the containment of HIV-1 replication subsequent to infection.

show abstract

Section: Determination Of Shiv Rna Viral Load By Sybr Green-based Quamentioning

confidence: 99%

Effects of Immunization with CCR5-Based Cycloimmunogen on Simian/HIVSF162P3 Challenge

Misumi

Nakayama

Kusaba

et al. 2006

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Animal lentiviral systems used as AIDS vaccine models have included simian/human immunodeficiency virus (SHIV)-monkey, simian immunodeficiency virus (SIV)-monkey, equine infectious anemia virus (EIAV)-horse, and feline immunodeficiency virus (FIV)-cat models (1). Interestingly, the greatest level of success has been realized with live attenuated animal lentivirus vaccines that are able to drive a critical maturation of virus-specific humoral and cellular immune responses (3,4,15,16,20,29,(36)(37)(38).…”

mentioning

confidence: 99%

Discerning an Effective Balance between Equine Infectious Anemia Virus Attenuation and Vaccine Efficacy

Craigo¹,

Feng²,

Steckbeck³

et al. 2005

J Virol

View full text Add to dashboard Cite

Among the diverse experimental vaccines evaluated in various animal lentivirus models, live attenuated vaccines have proven to be the most effective, thus providing an important model for examining critical immune correlates of protective vaccine immunity. We previously reported that an experimental live attenuated vaccine for equine infectious anemia virus (EIAV), based on mutation of the viral S2 accessory gene, elicited protection from detectable infection by virulent virus challenge (F. Li et al., J. Virol. 77:7244-7253, 2003). To better understand the critical components of EIAV vaccine efficacy, we examine here the relationship between the extent of virus attenuation, the maturation of host immune responses, and vaccine efficacy in a comparative study of three related attenuated EIAV proviral vaccine strains: the previously described EIAV UK ⌬S2 derived from a virulent proviral clone, EIAV UK ⌬S2/DU containing a second gene mutation in the virulent proviral clone, and EIAV PR ⌬S2 derived from a reference avirulent proviral clone. Inoculations of parallel groups of eight horses resulted in relatively low levels of viral replication (average of 10 2 to 10 3 RNA copies/ml) and a similar maturation of EIAV envelope-specific antibody responses as determined in quantitative and qualitative serological assays. However, experimental challenge of the experimentally immunized horses by our standard virulent EIAV PV strain by using a low-dose multiple exposure protocol (three inoculations with 10 median horse infective doses, administered intravenously) revealed a marked difference in the protective efficacy of the various attenuated proviral vaccine strains that was evidently associated with the extent of vaccine virus attenuation, time of viral challenge, and the apparent maturation of virus-specific immunity.

show abstract

“…The total viral DNA obtained after the purification procedure (29) was used for SYBR Green real-time PCR assay, as previously described (30), with some modifications. Briefly, primers that recognize specific and highly conserved sequences on the gag region of SIV described by Ui et al (31) were selected. The sequences of SIV gag primers were 5Ј-GGAAATTACCCAGTACAACAAATAGG-3Ј and 5Ј-TC TATCAATTTTACCCAGGCATTTA-3Ј.…”

Section: Determination Of Total Number Of Siv Dna Copiesmentioning

confidence: 99%

Targeted Delivery of Immunogen to Primate M Cells with Tetragalloyl Lysine Dendrimer

Misumi

Masuyama

Takamune

et al. 2009

The Journal of Immunology

View full text Add to dashboard Cite

Effective uptake of Ags by specialized M cells of gut-associated lymphoid tissues is an important step in inducing efficient immune responses after oral vaccination. Although stable nontoxic small molecule mimetics of lectins, such as synthetic multivalent polygalloyl derivatives, may have potential in murine M cell targeting, it remains unclear whether synthetic multivalent polygalloyl derivatives effectively target nonhuman and human M cells. In this study, we evaluated the ability of a tetragalloyl derivative, the tetragalloyl-d-lysine dendrimer (TGDK), to target M cells in both in vivo nonhuman primate and in vitro human M-like cell culture models. TGDK was efficiently transported from the lumen of the intestinal tract into rhesus Peyer’s patches by M cells and then accumulated in germinal centers. Oral administration of rhesus CCR5-derived cyclopeptide conjugated with TGDK in rhesus macaque resulted in a statistically significant increase in stool IgA response against rhesus CCR5-derived cyclopeptide and induced a neutralizing activity against SIV infection. Furthermore, TGDK was specifically bound to human M-like cells and efficiently transcytosed from the apical side to the basolateral side in the M-like cell model. Thus, the TGDK-mediated vaccine delivery system represents a potential approach for enabling M cell-targeted mucosal vaccines in primates.

show abstract

Protection of Macaques against a SHIV with a Homologous HIV-1 Env and a Pathogenic SHIV-89.6P with a Heterologous Env by Vaccination with Multiple Gene-Deleted SHIVs

Cited by 40 publications

References 71 publications

Effects of Immunization with CCR5-Based Cycloimmunogen on Simian/HIVSF162P3 Challenge

Effects of Immunization with CCR5-Based Cycloimmunogen on Simian/HIVSF162P3 Challenge

Discerning an Effective Balance between Equine Infectious Anemia Virus Attenuation and Vaccine Efficacy

Targeted Delivery of Immunogen to Primate M Cells with Tetragalloyl Lysine Dendrimer

Contact Info

Product

Resources

About